Barclays maintains Celanese at Equal-Weight, raises price target to $57 from $49

Barclays kept Celanese at Equal-Weight, raising its price target to $57 from $49, a 16.3% increase. This implies a 13.2% upside from the Nov 3 close of $50.36.

Original reporting
Published Nov 4, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 5:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Celanese at Equal-Weight, raises price target to $57 from $49 — source image
Decision brief

The 30-second read

$CEBullishLow
01

Why it matters

A higher price target can influence near-term sentiment, but without a rating upgrade or new fundamental information, the trading signal is likely modest.

02

Market read

Useful for tracking sell-side sentiment and potential short-term positioning, but not a standalone fundamental catalyst.

03

What to watch

Traders may discount the move if they expect the underlying fundamentals to drive price more than target revisions; the article lacks any new thesis details beyond the numbers.

Relevance 4/10Novelty 4/10Timing: as of the analyst note publication date, for positioning around PT changes

Background

The piece is an analyst action update from Barclays on Celanese, not a company disclosure.

Company-level read

Ticker impact

$CEBullishHigh confidence
Context

Barclays maintained Celanese at Equal-Weight and raised its price target to $57 from $49, implying upside versus the Nov 3 close.

Expected impact

Likely mild upward pressure or support as traders price in the higher target, though impact should be limited given the Equal-Weight rating.

Evidence & confidence

The only disclosed change is the analyst price target; the article provides no new company-specific operational, financial, or regulatory development.

Market effects

Limited read-through to the broader industrials/chemicals complex since this is a single-name analyst target change with no new sector data.

Minimal, as the catalyst is analyst commentary on a US-listed stock.

Low, no global macro or cross-border transaction details are provided.

Counterpoint

Equal-Weight is unchanged, so the PT hike may not translate into sustained buying pressure if investors view it as incremental or already anticipated.

Key entities

  • Celanese

    US-listed chemicals/materials company covered by Barclays; Equal-Weight maintained and price target raised to $57 from $49.

Related articles

$CEMed

BMO raises Celanese stock price target to $58 on cost cuts

BMO Capital increased its price target for Celanese (NYSE:CE) to $58 from $56, citing cost-cutting and cash generation. The firm expects higher estimates for 2027-2028 due to growth in engineered materials, despite challenges in the acetyl chain business. Celanese reported Q3 2026 earnings of $1.65 per share, beating estimates, but revenue fell short. Other analysts have also raised price targets.

$CEMed

Celanese Corp (CE) Q3 2026 Earnings Call Highlights: 2027 Free Cash Flow Outlook

Celanese Corp (CE) reported Q3 2026 earnings, with CFO Chuck Kyrish highlighting $70M in cost savings this year and $30M-$40M expected in 2027. CEO Scott Richardson noted strong demand from AI data center build-outs driving growth in electronics. Q4 guidance includes a 6-7% volume decline in Engineered Materials and a $25M decline in acetyls. The company expects margin compression in Q4 due to methanol prices and other cost pressures.

$CEMedAI 8/10

Celanese Q3 Earnings Call Highlights

Celanese (NYSE: CE) expects restructuring costs to decrease by $30M-$40M in 2027 and additional cost savings of $30M-$40M in 2027. The company targets $150M in productivity improvements to offset inflation. Engineered Materials segment sees growth in electronics and healthcare, while automotive and nylon conditions remain mixed. Acetyl Chain faces margin compression due to outages and cost pressures.

$CEMed

Celanese (CE) Q3 2026 Earnings Call Transcript

Celanese (CE) reported Q3 2026 earnings, highlighting $100M in cost savings for 2027 and $700M-$800M in free cash flow. The company expects growth in electronics and healthcare segments to continue into 2027, while addressing potential capacity needs in downstream derivatives. Management discussed market dynamics in Asia and the impact of tariff changes on VAM. According to the company, they remain focused on productivity and targeted investments.

$CEMedAI 8/10

Celanese Q3 2026 slides: specialty focus drives margin gains

Celanese (NYSE:CE) reported Q3 2026 earnings with revenue of $2.56B, missing estimates, but EPS of $1.65 beat expectations. The company highlighted strong free cash flow of $461M and raised full-year guidance to $750M-$800M. Shares rose 3.86% to $49.79. Celanese is shifting focus to high-margin specialty applications in medical and electronics, driving margin expansion.

$CEHighAI 8/10

Why is Celanese stock rallying today?

Celanese (CE) stock rose 4.3% in pre-market trading after reporting Q3 adjusted EPS of $1.65, beating estimates. Revenue grew 6% YoY to $2.56B, missing slightly. The company raised its full-year 2026 EPS guidance to $6.00–$6.25. Analysts Mizuho and BofA increased price targets. The S&P 500 and NASDAQ showed mild gains.